39
Participants
Start Date
September 14, 2007
Primary Completion Date
April 22, 2010
Study Completion Date
June 21, 2011
HDAC inhibitor SB939
SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.
immunoenzyme technique
immunohistochemistry staining method
immunologic technique
laboratory biomarker analysis
liquid chromatography
mass spectrometry
pharmacological study
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Univ. Health Network-Princess Margaret Hospital, Toronto
Lead Sponsor
S*BIO
INDUSTRY
NCIC Clinical Trials Group
NETWORK